Li Watsek
Stock Analyst at Cantor Fitzgerald
(2.48)
# 2,294
Out of 5,152 analysts
80
Total ratings
53.01%
Success rate
-1.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Li Watsek
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZLAB Zai Lab | Maintains: Overweight | $55 → $37 | $19.30 | +91.71% | 2 | Feb 27, 2026 | |
| TYRA Tyra Biosciences | Initiates: Overweight | n/a | $34.54 | - | 1 | Feb 24, 2026 | |
| AVBP ArriVent BioPharma | Initiates: Overweight | n/a | $25.25 | - | 1 | Dec 23, 2025 | |
| CMPX Compass Therapeutics | Initiates: Overweight | n/a | $5.53 | - | 1 | Dec 3, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $203 → $254 | $237.35 | +7.01% | 20 | Oct 13, 2025 | |
| CNTX Context Therapeutics | Initiates: Overweight | n/a | $2.86 | - | 1 | Oct 2, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | n/a | $33.03 | - | 3 | Sep 9, 2025 | |
| REPL Replimune Group | Upgrades: Overweight | n/a | $7.04 | - | 2 | Jul 30, 2025 | |
| KURA Kura Oncology | Reiterates: Overweight | n/a | $8.51 | - | 11 | Jun 26, 2025 | |
| ACRV Acrivon Therapeutics | Reiterates: Overweight | n/a | $1.60 | - | 2 | Mar 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $5.82 | - | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $13.72 | - | 5 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $2.13 | - | 7 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $22.21 | - | 4 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $5.35 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.02 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $16.06 | - | 5 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $5.28 | -43.18% | 4 | Nov 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $1.38 | +262.32% | 3 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $38 | $2.46 | +1,444.72% | 1 | Aug 12, 2022 |
Zai Lab
Feb 27, 2026
Maintains: Overweight
Price Target: $55 → $37
Current: $19.30
Upside: +91.71%
Tyra Biosciences
Feb 24, 2026
Initiates: Overweight
Price Target: n/a
Current: $34.54
Upside: -
ArriVent BioPharma
Dec 23, 2025
Initiates: Overweight
Price Target: n/a
Current: $25.25
Upside: -
Compass Therapeutics
Dec 3, 2025
Initiates: Overweight
Price Target: n/a
Current: $5.53
Upside: -
Ascendis Pharma
Oct 13, 2025
Maintains: Overweight
Price Target: $203 → $254
Current: $237.35
Upside: +7.01%
Context Therapeutics
Oct 2, 2025
Initiates: Overweight
Price Target: n/a
Current: $2.86
Upside: -
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: n/a
Current: $33.03
Upside: -
Replimune Group
Jul 30, 2025
Upgrades: Overweight
Price Target: n/a
Current: $7.04
Upside: -
Kura Oncology
Jun 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $8.51
Upside: -
Acrivon Therapeutics
Mar 26, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.60
Upside: -
Mar 14, 2025
Initiates: Overweight
Price Target: n/a
Current: $5.82
Upside: -
Feb 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $13.72
Upside: -
Jan 24, 2025
Reiterates: Overweight
Price Target: n/a
Current: $2.13
Upside: -
Oct 7, 2024
Reiterates: Overweight
Price Target: n/a
Current: $22.21
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $5.35
Upside: -
May 15, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.02
Upside: -
Apr 1, 2024
Reiterates: Overweight
Price Target: n/a
Current: $16.06
Upside: -
Nov 22, 2023
Reiterates: Overweight
Price Target: $3
Current: $5.28
Upside: -43.18%
Sep 7, 2023
Reiterates: Neutral
Price Target: $5
Current: $1.38
Upside: +262.32%
Aug 12, 2022
Maintains: Overweight
Price Target: $60 → $38
Current: $2.46
Upside: +1,444.72%